Apellis Pharmaceuticals Inc (APLS)
28.04
-0.19
(-0.67%)
USD |
NASDAQ |
Nov 14, 16:00
28.04
0.00 (0.00%)
After-Hours: 18:02
Apellis Pharmaceuticals Research and Development Expense (Quarterly): 88.57M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 88.57M |
| June 30, 2024 | 77.95M |
| March 31, 2024 | 84.70M |
| December 31, 2023 | 69.28M |
| September 30, 2023 | 79.42M |
| June 30, 2023 | 95.66M |
| March 31, 2023 | 110.03M |
| December 31, 2022 | 99.42M |
| September 30, 2022 | 95.21M |
| June 30, 2022 | 101.66M |
| March 31, 2022 | 90.94M |
| December 31, 2021 | 103.18M |
| September 30, 2021 | 87.73M |
| June 30, 2021 | 145.94M |
| March 31, 2021 | 84.01M |
| December 31, 2020 | 50.34M |
| September 30, 2020 | 93.21M |
| June 30, 2020 | 87.09M |
| March 31, 2020 | 69.28M |
| Date | Value |
|---|---|
| December 31, 2019 | 78.47M |
| September 30, 2019 | 51.32M |
| June 30, 2019 | 50.70M |
| March 31, 2019 | 40.48M |
| December 31, 2018 | 30.81M |
| September 30, 2018 | 29.54M |
| June 30, 2018 | 27.54M |
| March 31, 2018 | 17.40M |
| December 31, 2017 | 13.13M |
| September 30, 2017 | 9.518M |
| June 30, 2017 | 10.42M |
| March 31, 2017 | 7.231M |
| December 31, 2016 | 5.592M |
| September 30, 2016 | 6.234M |
| December 31, 2015 | 3.928M |
| September 30, 2015 | 3.745M |
| December 31, 2014 | 1.889M |
| September 30, 2014 | 1.997M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
50.34M
Minimum
Dec 2020
145.94M
Maximum
Jun 2021
89.61M
Average
88.15M
Median
Research and Development Expense (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 184.90M |
| Ionis Pharmaceuticals Inc | 219.76M |
| EyePoint Pharmaceuticals Inc | 29.82M |
| Cassava Sciences Inc | 17.68M |
| Macrogenics Inc | 40.54M |